Evolent Health (NYSE:EVH) Given Market Outperform Rating at JMP Securities

Evolent Health (NYSE:EVH)‘s stock had its “market outperform” rating reiterated by stock analysts at JMP Securities in a research report issued on Friday,Benzinga reports. They currently have a $12.00 target price on the technology company’s stock. JMP Securities’ target price points to a potential upside of 18.23% from the company’s previous close.

Several other equities research analysts have also commented on EVH. JPMorgan Chase & Co. lowered their price target on shares of Evolent Health from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. BTIG Research dropped their target price on Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, December 3rd. Oppenheimer decreased their price target on Evolent Health from $28.00 to $18.00 and set an “outperform” rating for the company in a report on Friday, January 24th. Stephens dropped their price objective on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Tuesday, January 21st. Finally, Canaccord Genuity Group decreased their target price on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. One analyst has rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $17.92.

Evolent Health Stock Performance

NYSE EVH traded up $0.18 on Friday, hitting $10.15. 295,621 shares of the company’s stock traded hands, compared to its average volume of 2,040,062. The firm has a market capitalization of $1.18 billion, a PE ratio of -11.16 and a beta of 1.45. Evolent Health has a 1-year low of $9.45 and a 1-year high of $35.00. The firm’s 50-day moving average price is $10.88 and its two-hundred day moving average price is $19.37. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58.

Institutional Investors Weigh In On Evolent Health

Large investors have recently bought and sold shares of the company. Royce & Associates LP purchased a new stake in shares of Evolent Health during the third quarter worth approximately $7,070,000. Foundry Partners LLC acquired a new stake in shares of Evolent Health in the third quarter valued at about $10,042,000. Salem Investment Counselors Inc. boosted its holdings in shares of Evolent Health by 53.0% during the 4th quarter. Salem Investment Counselors Inc. now owns 350,155 shares of the technology company’s stock worth $3,939,000 after purchasing an additional 121,369 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in Evolent Health by 140.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 422,421 shares of the technology company’s stock valued at $11,946,000 after buying an additional 246,400 shares during the period. Finally, Nordea Investment Management AB grew its holdings in shares of Evolent Health by 7.0% in the fourth quarter. Nordea Investment Management AB now owns 130,453 shares of the technology company’s stock valued at $1,469,000 after purchasing an additional 8,552 shares in the last quarter.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.